Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: A phase I/II study in patients in complete haematological remission

British Journal of Haematology

Volumn 137, Issue 5, 2007, Pages 423-428

  Pavlu, Jiri ^a   Andreasson, Catharina ^a   Chuah, Charles ^b   Kaeda, Jaspal ^a   Goldman, John M ^a   Apperley, Jane F ^a   Marin, David ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Bisphosphonate; Chronic myeloid leukaemia; Imatinib; Zoledronate; Zoledronic acid

Indexed keywords

BCR ABL PROTEIN; CALCIUM; IMATINIB; ZOLEDRONIC ACID;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD TOXICITY; BONE MARROW EXAMINATION; CANCER PATIENT; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLU LIKE SYNDROME; HUMAN; HYPOCALCEMIA; HYPOPHOSPHATEMIA; LEUKEMIA REMISSION; MALE; MONOTHERAPY; MUSCLE CRAMP; MYALGIA; NAUSEA; PATIENT COMPLIANCE; PATIENT MONITORING; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SHIVERING; SIDE EFFECT; SIGNAL TRANSDUCTION; SORE THROAT; SWEATING; TREATMENT DURATION; VOMITING;

ADULT; ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; CYTOGENETIC ANALYSIS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; RAS PROTEINS; REMISSION INDUCTION; SIGNAL TRANSDUCTION;

EID: 34247893689     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06578.x     Document Type: Article

References (18)

1. Baccarani, M., Saglio, G., Goldman, J., Hochhaus, A., Simonsson, B., Appelbaum, F., Apperley, J., Cervantes, F., Cortes, J., Deininger, M., Gratwohl, A., Guilhot, F., Horowitz, M., Hughes, T., Kantarjian, H., Larson, R., Niederwieser, D., Silver, R. Hehlmann, R. (2006) Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European Leukemianet. Blood, 108, 1809 1820.
2. Berenson, J.R., Vescio, R., Henick, K., Nishikubo, C., Rettig, M., Swift, R.A., Conde, F. Von Teichert, J.M. (2001a) A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer, 91, 144 154.
3. Berenson, J.R., Rosen, L.S., Howell, A., Porter, L., Coleman, R.E., Morley, W., Dreicer, R., Kuross, S.A., Lipton, A. Seaman, J.J. (2001b) Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer, 91, 1191 1200.
4. Chen, T., Berenson, J., Vescio, R., Swift, R., Gilchick, A., Goodin, S., LoRusso, P., Ma, P., Ravera, C., Deckert, F., Schran, H., Seaman, J. Skerjanec, A. (2002) Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. Journal of Clinical Pharmacology, 42, 1228 1236.
5. Chuah, C., Barnes, D.J., Kwok, M., Corbin, A., Deininger, M.W., Druker, B.J. Melo, J.V. (2005) Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells. Leukemia, 19, 1896 1904.
6. Cross, N.C., Feng, L., Chase, A., Bungey, J., Hughes, T.P. Goldman, J.M. (1993) Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood, 82, 1929 1936.
7. Goldman, J.M. Melo, J.V. (2003) Chronic myeloid leukemia - advances in biology and new approaches to treatment. New England Journal of Medicine, 349, 1451 1464.
8. Hiraga, T., Williams, P.J., Mundy, G.R. Yoneda, T. (2001) The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Research, 61, 4418 4424.
9. Hughes, T.P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M.L., Gathmann, I., Bolton, A.E., van Hoomissen, I.C., Goldman, J.M. Radich, J.P. (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. New England Journal of Medicine, 349, 1423 1432.
10. Khorashad, J.S., Anand, M., Marin, D., Saunders, S., Al-Jabary, T., Iqbal, A., Margerison, S., Melo, J.V., Goldman, J.M., Apperley, J.F. Kaeda, J. (2006) The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia, 20, 658 663.
11. Kuroda, J., Kimura, S., Segawa, H., Kobayashi, Y., Yoshikawa, T., Urasaki, Y., Ueda, T., Enjo, F., Tokuda, H., Ottmann, O.G. Maekawa, T. (2003) The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. Blood, 102, 2229 2235.
12. Marin, D., Kaeda, J., Szydlo, R., Saunders, S., Fleming, A., Howard, J., Andreasson, C., Bua, M., Olavarria, E., Rahemtulla, A., Dazzi, F., Kanfer, E., Goldman, J.M. Apperley, J.F. (2005) Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse. Leukemia, 19, 507 512.
13. O'Brien, S.G., Guilhot, F., Larson, R.A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J.J., Fischer, T., Hochhaus, A., Hughes, T., Lechner, K., Nielsen, J.L., Rousselot, P., Reiffers, J., Saglio, G., Shepherd, J., Simonsson, B., Gratwohl, A., Goldman, J.M., Kantarjian, H., Taylor, K., Verhoef, G., Bolton, A.E., Capdeville, R. Druker, B.J. (2003a) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New England Journal of Medicine, 348, 994 1004.
14. O'Brien, S., Giles, F., Talpaz, M., Cortes, J., Rios, M.B., Shan, J., Thomas, D., Andreeff, M., Kornblau, S., Faderl, S., Garcia-Manero, G., White, K., Mallard, S., Freireich, E. Kantarjian, H.M. (2003b) Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer, 98, 888 893.
15. Puil, L., Liu, J., Gish, G., Mbamalu, G., Bowtell, D., Pelicci, P.G., Arlinghaus, R. Pawson, T. (1994) Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. European Molecular Biology Organization Journal, 13, 764 773.
16. Rebollo, A. Martinez, A. (1999) Ras proteins: recent advances and new functions. Blood, 94, 2971 2980.
17. Rogers, M.J., Gordon, S., Benford, H.L., Coxon, F.P., Luckman, S.P., Monkkonen, J. Frith, J.C. (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer, 88, 2961 2978.
18. Rosen, L.S., Gordon, D., Kaminski, M., Howell, A., Belch, A., Mackey, J., Apffelstaedt, J., Hussein, M.A., Coleman, R.E., Reitsma, D.J., Chen, B.L. Seaman, J.J. (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer, 98, 1735 1744.